Potential confounding factors—such as age, sex, cancer type and stage, cardiovascular risk factors, and concurrent cardiovascular medications—were adjusted to varying degrees in the analysis of SGLT2 inhibitor use and CTRCD risk. The gene discussed is SLC5A2; the disease is cancer.